For genetic testing, it is proposed to conduct the strong candidate gene sequencing first (SCN1A for Dravet syndrome, MECP2 for Rett syndrome and TSC1/2 for tuberous sclerosis complex) before a NGS multi-gene panel testing [95–97]. This evidence concerns the gene MECP2 and Dravet syndrome.